Loading...
XKRX
086900
Market cap838mUSD
May 27, Last price  
172,900.00KRW
1D
3.22%
1Q
30.39%
Jan 2017
-51.51%
IPO
9.78%
Name

Medy Tox Inc

Chart & Performance

D1W1MN
XKRX:086900 chart
No data to show
P/E
67.90
P/S
5.04
EPS
2,546.47
Div Yield, %
—
Shrs. gr., 5y
0.80%
Rev. gr., 5y
2.12%
Revenues
228.62b
+3.39%
36,262,446,94039,141,030,12075,892,308,00088,505,437,514133,255,671,034181,239,191,116205,444,934,515205,900,275,787140,827,514,747184,869,547,955195,096,220,132221,120,682,590228,621,969,000
Net income
16.95b
+73.81%
15,436,739,78014,303,536,78043,627,867,04042,292,784,52859,231,019,51570,106,132,63769,963,675,93326,205,603,001-29,576,742,63694,153,921,07037,009,995,3709,755,098,73016,954,995,000
CFO
36.56b
+170.36%
14,779,384,52016,596,271,730105,379,387,53023,259,440,53653,443,912,35554,655,924,75453,462,056,56131,976,962,33925,746,780,92116,681,715,09924,135,315,71813,521,518,66036,556,164,000
Dividend
Sep 26, 2023952.38098 KRW/sh
Earnings
Aug 07, 2025

Profile

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual and Recell Ice for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method; and Careveam for treating skin ailment by using ultraviolet light. Further, the company offers Neurakin cream for acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea dermatitis, perioral dermatitis, herpes zoster, and acne vulgaris. It also exports its products to approximately 60 countries, including Japan, Thailand, and Brazil. Medytox, Inc. has partnership with Dyadic International, Inc. to develop vaccines against COVID-19 variants. The company was founded in 2000 and is headquartered in Cheongju, South Korea.
URL
http://www.medytox.com/
IPO date
Jan 16, 2009
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
228,621,969
3.39%
221,120,683
13.34%
195,096,220
5.53%
Cost of revenue
174,022,873
173,818,752
118,457,036
Unusual Expense (Income)
NOPBT
54,599,096
47,301,931
76,639,184
NOPBT Margin
23.88%
21.39%
39.28%
Operating Taxes
1,425,399
6,163,181
12,930,301
Tax Rate
2.61%
13.03%
16.87%
NOPAT
53,173,697
41,138,750
63,708,883
Net income
16,954,995
73.81%
9,755,099
-73.64%
37,009,995
-60.69%
Dividends
(8,424,486)
(8,422,101)
(8,044,577)
Dividend yield
1.00%
0.52%
0.96%
Proceeds from repurchase of equity
(10,006,878)
6,971,148
12,634,207
BB yield
1.19%
-0.43%
-1.50%
Debt
Debt current
60,038,399
81,604,285
100,526,465
Long-term debt
23,290,459
2,976,898
20,335,948
Deferred revenue
335,948
Other long-term liabilities
5,236,909
9,128,927
6,256,010
Net debt
(38,542,856)
(62,339,919)
(105,418,399)
Cash flow
Cash from operating activities
36,556,164
13,521,519
24,135,316
CAPEX
(8,725,950)
(7,659,593)
(25,100,506)
Cash from investing activities
(646,923)
13,254,810
(36,472,529)
Cash from financing activities
(24,047,920)
(13,543,577)
(37,974,766)
FCF
79,563,652
23,027,056
34,792,889
Balance
Cash
59,514,961
33,345,129
26,208,405
Long term investments
62,356,753
113,575,972
200,072,407
Excess cash
110,440,616
135,865,067
216,526,001
Stockholders' equity
433,389,072
417,841,516
323,725,331
Invested Capital
446,898,773
430,576,192
336,215,220
ROIC
12.12%
10.73%
20.71%
ROCE
9.79%
8.35%
13.84%
EV
Common stock shares outstanding
6,731
6,697
6,565
Price
124,800.00
-48.22%
241,000.00
88.28%
128,000.00
-6.60%
Market cap
840,045,398
-47.95%
1,613,963,263
92.08%
840,260,864
-4.01%
EV
806,351,308
1,556,863,187
740,656,346
EBITDA
74,557,865
62,677,650
91,949,981
EV/EBITDA
10.82
24.84
8.05
Interest
1,726,893
2,332,980
2,313,515
Interest/NOPBT
3.16%
4.93%
3.02%